Endogenous Endophthalmitis in the Inpatient Setting

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Stanford University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Theodore Leng, Stanford University
ClinicalTrials.gov Identifier:
NCT01323868
First received: March 24, 2011
Last updated: March 22, 2012
Last verified: March 2012
  Purpose

The purpose of this study is to determine the rate of endogenous endophthalmitis in patients admitted to Stanford Hospital with a systemic infection and positive blood cultures, as this may improve the clinical care of this population of patients.


Condition
Endophthalmitis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Endogenous Endophthalmitis Rates, Clinical Course, and Outcomes

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Positive intraocular infection [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Visual acuity [ Time Frame: 2 wk ] [ Designated as safety issue: No ]

Estimated Enrollment: 390
Study Start Date: July 2010
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Some patients admitted to the hospital have blood-borne infections. Occasionally, these blood infections can end up inside the eye and cause an infection inside the eye (called endogenous endophthalmitis).

Prior to modern and rapid treatment of systemic infections, the rate of endogenous endophthalmitis was reported to be 37% in 1982. By 1997, the rate was reported to be 2.8%. This study aims to determine the rate of endogenous endophthalmitis at Stanford Hospital in the modern medical era in that our rates may be different as those reported in the literature. This potential difference may be a reflection of treatment protocols and antibiotics currently in use at Stanford Hospital.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Inpatients at Stanford Hospital with positive blood cultures who receive an Ophthalmology consultation and eye examination.

Criteria

Inclusion Criteria:All patients admitted to Stanford Hospital that have a systemic blood-borne infection and on which an Ophthalmology consult to rule out endogenous endophthalmitis is performed will be included in the study.

Exclusion Criteria:None

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01323868

Contacts
Contact: Theodore Leng, MD (650) 723-6995

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Theodore Leng, MD    650-723-6995      
Principal Investigator: Theodore Leng         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Theodore Leng Stanford University
  More Information

No publications provided

Responsible Party: Theodore Leng, Clinical Assistant Professor of Ophthalmology, Stanford University
ClinicalTrials.gov Identifier: NCT01323868     History of Changes
Other Study ID Numbers: SU-03232011-7621, IRB-18785
Study First Received: March 24, 2011
Last Updated: March 22, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Endophthalmitis
Eye Infections
Infection
Eye Diseases

ClinicalTrials.gov processed this record on July 29, 2014